ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0021 • ACR Convergence 2025

    DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies

    Antonio Julià1, Yolanda Guillén2, Paloma Vela Casasempere3, Antonio Fernández Nebro4, Carlos Marras5, Santos Castañeda6, Jaime Calvo Alén7, Jesús Tornero Molina8, Juan Cañete9, Eugeni Domènech10, Javier Gisbert11, Jose M. Carrascosa12, Eduardo Fonseca13, Luis Bujanda Fernández De pierola14, Valle García Sánchez15, Britta Siegmund16, Giampiero Girolomoni17, Holger Heyn18, Laura Jiménez Gracia18, Pere Santamaria19, Edgar Angelats20, Richard Myers21, Sergio H. Martínez Mateu2, Juan Ángel Patiño Galindo2, Ernest Choy22 and Sara Marsal1, 1Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, 2IMIDomics, Barcelona, Spain, 3Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain, 4Hospital Regional Universitario Carlos Haya, Rheumatology, Málaga, Spain, 5Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Spain, 6Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 7Hospital Universitario de Araba, Rheumatology, Vitoria, Spain, 8Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain, 9Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 11Hospital Universitario La Princesa, Rheumatology, Madrid, Spain, 12Hospital Universitari Germans Trias i Pujol, Dermatology, Badalona, Spain, 13Complejo Hospitalario Universitario de A Coruña, Dermatology, A Coruña, Spain, 14Hospital Universitario de Donostia, Gastroenterology, San Sebastián, Spain, 15Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, 16Charité-Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany, 17University of Verona, Dermatology, Verona, Spain, 18Centre for Genomic Regulation (CNAG-CRG), Barcelona, Spain, 19Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelonoa, Spain, 20Hospital Clínic-IDIBAPS, Barcelona, Spain, 21HudsonAlpha Institute for Biotechnology, Huntsville, AL, 22Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom

    Background/Purpose: Targeted therapies have revolutionized the management of immune-mediated inflammatory diseases (IMIDs), however, there is a substantial number of patients who respond poorly to a…
  • Abstract Number: 2611 • ACR Convergence 2025

    Exploring the Role of a Lung Ultrasound Score in the Assessment of Severity of Connective Tissue Disease-Related Interstitial Lung Disease

    jin ding1, ying zhang1, Linxuan Pang1, ning guo2 and zhaohui zheng1, 1Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), 2Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic)

    Background/Purpose: The role of lung ultrasound (LUS) in assessing disease severity of interstitial lung disease (ILD) remains unclear. We employed a semiquantitative scoring system to…
  • Abstract Number: 2535 • ACR Convergence 2025

    Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region

    Ricardo Machado1, Thales Souza2, Matheus França3, Vinicius Matias4, Sylvia Farhat1, Carolina Siqueira4, Maria Carolina Santos4, Lia Steuer1, Luisa Forero1, Rafael Bassara Macedo5, Thiago Freitas6, barbara Bayeh7, Carolina Ejnisman8, Pedro Araujo9, Rafael Cordeiro10, Fabio Specian5, Verena Balbi1, Nadia Emi Aikawa11, Katia Kozu1, Clovis Artur Silva12, Lucia Maria Campos13, Adriana Elias14 and Henrique Giardini6, 1Instituto da Criança e do Adolescente, Hospital das Clinicas, Sao Paulo, Sao Paulo, Brazil, 2Faculdade de Medicina da Universidade de Brasilia, Brasilia, Distrito Federal, Brazil, 3Instituto da Criança e do Adolescente, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil, 4Faculdade de Ciências Medicas da Santa Casa de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 5Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, 6Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, 7Hospital das Clínicas, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil, 8Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 9Universidade de São Paulo, Sao Paulo, São Paulo, Brazil, 10Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, 11Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, 12University of São Paulo, São Paulo, São Paulo, Brazil, 13Instituto da Criança e do Adolescente, São Paulo, São Paulo, Brazil, 14Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas, University of Sao Paulo Medical School, São Paulo, São Paulo, Brazil

    Background/Purpose: Behçet’s syndrome (BS) is a chronic inflammatory disorder characterized by a heterogeneous clinical presentation, occurring primarily in young adults and very rarely in children…
  • Abstract Number: 2409 • ACR Convergence 2025

    Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study

    Joseph F Merola1, Weihong Yang2, Qianyun Li2, Helen Doll3, Jason Randall3, Catherine Barbey4 and Feng Zeng2, 1Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 2Biogen, Cambridge, MA, 3Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom, 4Biogen, Baar, Switzerland

    Background/Purpose: The Cutaneous Lupus Activity Investigator’s Global Assessment-Revised (CLA-IGA-R) is an emerging clinician-reported outcome measure for severity of Cutaneous Lupus Erythematosus (CLE) disease activity, developed…
  • Abstract Number: 2034 • ACR Convergence 2025

    Hidden Burden in Rheumatology: Cross-Sectional Study of Hearing Loss in Systemic Autoimmune Diseases

    Ruddy Paola Montoya Rumpf1, Liliam María Murcia Munévar1, Jairo Cajamarca-Baron2, Dominique Daniela González Casas1, María Fernanda González Sánchez1, Adriana Rojas-Villarraga3, Henry Leonardo Martínez Bejarano1, Adriana Isaza1, Alejandro Escobar1, Maria Camila Restrepo Guarnizo1, Nicolás Santiago Rodríguez1 and Claudia Ibáñez-Antequera1, 1Fundacion universitaria de ciencias de la salud, bogota, Distrito Capital de Bogota, Colombia, 2Fundacion universitaria de ciencia de la Salud, Bogota, Distrito Capital de Bogota, Colombia, 3Fundacion Universitaria de Ciencias de la salud, Bogotá, Distrito Capital de Bogota, Colombia

    Background/Purpose: Autoimmune inner ear disease is a progressive sensorineural hearing loss of autoimmune origin, often underdiagnosed due to the lack of specific criteria, and requires…
  • Abstract Number: 1864 • ACR Convergence 2025

    Mitochondrial Dysfunction Drives cGAS-STING–Mediated Type I Interferon Production and Fibrosis in Systemic Sclerosis

    Giulio Forte1, Vasiliki Liakouli1, Alessia Salzillo2, Mario Angeli3, Daniele Mauro1, Antonio Ciancio1, Barbara De Marino2, Iacopo Panarese1, Mario Faenza1, roberto giacomelli4, Andreas Ramming5 and Francesco Ciccia6, 1Università della Campania Luigi Vanvitelli, Naples, Italy, 2University of Campania L. Vanvitelli, Naples, Italy, 3Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 4Università Campus Bio-Medico, Roma, Italy, 5Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, 6Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by type I interferon (IFN-I) production and mitochondrial dysfunction. Emerging evidence suggests that activation of the…
  • Abstract Number: 1701 • ACR Convergence 2025

    Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen

    Vibha Jha1, Brian Freed2, Niyun Jin1, Manjula Miglani1 and Christina Roark2, 1University of Colorado, Aurora, CO, 2Clinimmune Labs Immunology, School of Medicine, Aurora, CO

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease with a strong genetic association to Class II HLA-DRB1*04:01. Presentation of arthritogenic peptides bound to DRB1*04:01…
  • Abstract Number: 1545 • ACR Convergence 2025

    Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study

    Susan Manzi1, Ian Bruce2, Eric Morand3, Richard Furie4, Yoshiya Tanaka5, Patricia Puzio6, Emon Khan7, Jenny Wissmar8, Michael Song9 and Catharina Lindholm10, 1Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 2Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, 3Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, 4Division of Rheumatology, Northwell Health, Great Neck, NY, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, MD, 7BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, 8BioPharmaceuticals R&D, Late-Stage Development, Respiratory & Immunology, AstraZeneca, Gothenburg, Sweden, 9BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, MA, 10BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…
  • Abstract Number: 1401 • ACR Convergence 2025

    Real World Treatment Patterns and Health Care Resource Use in Patients With Newly Diagnosed Sjögren’s Disease (SjD) in the United States

    Sara McCoy1, Anjana Lalla2, Nilesh Choudhary3, Shraddha Chatterjee3, Shiwani Prasad3 and Antton Egana2, 1University of Wisconsin–Madison, Madison, WI, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3Novartis India, Hyderabad, India

    Background/Purpose: SjD is a chronic, systemic, progressive autoimmune disease characterized by dry mouth and eyes, but it is often accompanied by extraglandular symptoms and signs…
  • Abstract Number: 1248 • ACR Convergence 2025

    Patient and Clinician Perception and Use of Complementary and Alternative (CAM) Medicine for Rheumatic Disease

    Ailia Ali1, Sarah Sun1, Faryal Shaikh1, Tamiko Katsumoto2, Neha Shah3, Kimberly Trotter1 and Pankti Reid4, 1University of Chicago, Chicago, IL, 2Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, 3Stanford University, Palo Alto, CA, 4University of Chicago Medical Center, Chicago, IL

    Background/Purpose: Complementary and alternative medicine (CAM) use is increasingly prevalent among patients with rheumatic diseases, yet alignment between patient practices and clinician perspectives remains poorly…
  • Abstract Number: 1114 • ACR Convergence 2025

    Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine

    Mei-Feng Shi1, Fang-Shu Zou1, Xiao-Na Ma1, Wei Feng1, Yi-Fang Zhang2, Chang-Song Lin1, Min-Ying Liu2 and Qiang Xu1, 1Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), 2The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic)

    Background/Purpose: Methotrexate (MTX) is a first-line treatment for autoimmune diseases, including rheumatoid arthritis (RA). Its potential risk of inducing type 2 diabetes mellitus (T2DM) remains…
  • Abstract Number: 0989 • ACR Convergence 2025

    Human MAIT cell produce IL-17 independently of IL-23 and TL1A

    Kevin Hsu, Jessica Shannon, Zhiwei Fang, Anusara Daenthanasanmak, Prasad Srikakulapu, Tatiana Ort and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Mucosal-associated invariant T (MAIT) cells represent a specialized subset of T cells that exhibit innate-like, effector functions and have been implicated in the pathogenesis…
  • Abstract Number: 0926 • ACR Convergence 2025

    Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety

    Minyun Zhou1, Peng Gu2, Mengyu Wang3, Yuxi Yan2, Li Sun3, Yiling Chen3, Xin Wang3, Feng Tang1, Shunwei Zhu2 and Xiaofeng Zhao4, 1State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, 2State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), 3State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), 4State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)

    Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
  • Abstract Number: 0699 • ACR Convergence 2025

    A Retrospective Comparison of Transplant Outcomes in Patients with and without Systemic Sclerosis

    Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY

    Background/Purpose: Scleroderma renal crisis (SRC) is one of the life threatening complications of systemic sclerosis (SSc). Up to 20-50% require long term dialysis and subsequently…
  • Abstract Number: 0862 • ACR Convergence 2025

    In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis

    Margherita Giannini1, Giulia Quiring2, Mustapha Oulad-Abdelghani3, Béatrice Lannes1, Yves Allenbach4, Olivier Benveniste5, Olivier Boyer6, Aleksandra Nadaj Pakleza1, Bernard Geny7 and Alain Meyer8, 1Strasbourg University Hospital, Strasbourg, France, 2University of Strasbourg, Strasbourg, France, 3IGBMC, Strasbourg, France, 4SORBONNE UNIVERSITE, Paris, France, 5Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, 6University of Rouen, Rouen, France, 7UR 3072, Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, 8Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR 3072, Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France

    Background/Purpose: The aim of this study was to investigate whether in immune-mediated necrotising myopathy (IMNM), anti-HMGCR antibodies interfere with HMGCR activity and have a myopathic…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 101
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology